- Home
- / Zentalis Pharmaceuticals
Zentalis Pharmaceuticals
Stock Price
$2.8
2024-10-29
Market Capitalization
$201.9 M
2024-10-29
Revenue
$67.4 M
FY, 2024
Zentalis Pharmaceuticals Summary
Company Summary
- Overview
- Zentalis is a biopharmaceutical company. It focuses on developing clinically differentiated and small molecule therapeutics. The company aims to address major unmet medical needs for patients with cancer.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- New York, NY, US | view all locations
- Website
- https://www.zentalis.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Melissa Epperly, Chief Financial Officer
Peter Huang, Sr. Vice President, Discovery Research
Kimberley Overs, Vice President, General Counsel
LocationsView all
2 locations detected
New York, NY HQ
United States
530 7th Ave #2201
San Diego, CA
United States
10835 Rd to the Cure STE 205
Zentalis Pharmaceuticals Financials
Summary Financials
- Net income (FY, 2025)
- ($137.1M)
- Cash (FY, 2025)
- $36.0M
- EBIT (FY, 2025)
- ($152.8M)
- Enterprise value
- $241.2M